Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 11/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.36 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.36 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16927744 | 0.90 | SLC40A1 (0.36) | ENPP2SLC40A1KLKB1 | |
| SCHEMBL16927720 | 0.86 | SLC40A1 (0.41) | SLC40A1KLKB1 | |
| SCHEMBL2810078 | 0.82 | TRPC3 (0.37) | ENPP2GRIN2BTRPC3TRPC7ATXN2 | |
| SCHEMBL2806515 | 0.79 | ENPP2 (0.42) | ENPP2GRIN2BTRPC3TRPC7ATXN2 | |
| SCHEMBL2809066 | 0.78 | GRIN2B (0.47) | ENPP2GRIN2BTRPC3TRPC7 | |
| SCHEMBL2806832 | 0.77 | JAK2 (0.44) | ENPP2TRPC3TRPC7 | |
| SCHEMBL2809050 | 0.77 | ENPP2 (0.43) | ENPP2TRPC3TRPC7ATXN2 | |
| SCHEMBL2809173 | 0.76 | ENPP2 (0.43) | ENPP2 | |
| SCHEMBL2809162 | 0.76 | ENPP2 (0.41) | ENPP2KLKB1GRIN2BTRPC3TRPC7 | |
| SCHEMBL2806643 | 0.76 | ENPP2 (0.43) | ENPP2TRPC3TRPC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | claimed |
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240676-A1 | THIAZOLE DERIVATIVES | CCNE2, PKD1, PKD2 | ENPP2 4652/4885SLC40A1 1143/4885KLKB1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.